Sevoflurane requirement during elective ankle day surgery: the effects of etirocoxib premedication, a prospective randomised study

Turan, İbrahim; Hein, Anette; Jacobson, Eva; Jakobsson, Jan

doi:10.1186/1749-799x-3-40

Cited by 3 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These characteristics make them attractive candidates for perioperative use (Viola et al 2007 ; Schwartz et al 2008 ). Etoricoxib (a new selective COX-2 inhibitor available in many countries) has been reported to reduce postoperative pain after orthopedic surgery (Toivonen et al 2007 ; Turan et al 2008 ). When administered postoperatively to patients who had undergone hip replacement, etoricoxib provided analgesia similar to controlled release naproxen and superior to placebo (Rasmussen et al 2005 ).…”

Section: Introductionmentioning

confidence: 99%

Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery—a pilot study

Renner

Zacher

Buvanendran

et al. 2010

Naunyn-Schmied Arch Pharmacol

View full text Add to dashboard Cite

The perioperative administration of selective cyclooxygenase-2 (COX-2)-inhibitors to avoid postoperative pain is an attractive option: they show favorable gastro-intestinal tolerability, lack inhibition of blood coagulation, and carry a low risk of asthmatic attacks. The purpose of this study was to determine the cerebrospinal fluid (CSF), plasma, and tissue pharmacokinetics of orally administered etoricoxib and to compare it with effect data, i.e., COX-2-inhibition in patients after hip surgery. The study was performed in a blinded, randomized, parallel group design. A total of 12 adult patients were included who received 120 mg etoricoxib (n = 8) or placebo (n = 4) on day 1 post-surgery. Samples from plasma, CSF, and tissue exudates were collected over a period of 24 h post-dosing and analyzed for etoricoxib and prostaglandin E2 (PGE2) using liquid chromatography-tandem mass spectrometry and immuno-assay techniques. CSF area under the curve (AUC) [AUCs(O–24h)] for etoricoxib amounted to about 5% of the total AUC in plasma (range: 2–7%). Individual CSF lag times with respect to (50%) peak plasma concentration were ≤2 h in all but one case (median: 1 h). PGE2 production in tissue was significantly blocked by the COX-2 inhibitor starting with the appearance of etoricoxib in tissue and lasting for the whole observation period of 24 h (P < 0.01). In conclusion, etoricoxib reaches the CSF and site of surgery at effective concentrations and reduces PGE2 production at the presumed site of action.

show abstract

Section: Introductionmentioning

confidence: 99%

Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery—a pilot study

Renner

Zacher

Buvanendran

et al. 2010

Naunyn-Schmied Arch Pharmacol

View full text Add to dashboard Cite

show abstract

“…Therefore, pre-emptive analgesia can reduce immediate postoperative pain and also prevent the development of chronic pain by decreasing the altered central sensory processing. 20,21 Several studies have examined of the use of etoricoxib and have confirmed its efficacy in providing pain relief after gynaecological procedures (Liu et al, 2005, 22 Chau-in et al, 2008 23 ), after laparoscopic surgery (Puura et al, 2006 6 ), after thyroid surgery (Smirnov et al, 2008 12 ), after orthopaedic surgery (Peter et al, 2012 24 , Rasmussen et al, 2005, 25 Ibrahim et al, 2008, 26 Sowbhagya et al, 2014 27 ) and after trauma surgery (Siddiqui et al, 2008). 28 Our work studies the efficacy of a single dose of etoricoxib administered preoperatively in reducing the intraoperative anaesthetic and postoperative analgesic requirements in patients undergoing open inguinal hernioplasty under general anaesthesia.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Pre-Emptive Etoricoxib in Patients Undergoing Hernioplasty Under General Anaesthesia- A Prospective Randomised-Controlled Trial

Peter¹,

Alapatt²,

C.V³

2017

jebmh

View full text Add to dashboard Cite

BACKGROUND Obtaining adequate analgesia in the perioperative period is an enormous task. Studies show that etoricoxib, a selective COX-2 inhibitor given pre-emptively reduces the pain and thereby enhances recovery. The aim of the study is to evaluate the effect of pre-emptive etoricoxib in reducing intraoperative requirements of anaesthetic agents, decreasing postoperative pain and improving functional outcome in patients undergoing inguinal hernioplasty. MATERIALS AND METHODS Two groups, each of thirty patients were formed-Group S and Group C. Group S received a single dose of etoricoxib two hours prior to anaesthesia, while Group C received a placebo. Sevoflurane used during the intraoperative period was calculated. The patient's pain, sleep and body language in the postoperative period was noted. The rescue analgesics were recorded. Statistical Analysis-The data was analysed using Mann-Whitney U test, Wilcoxon test, independent two sample t-test, Pearson Chi-square test and Fischer's exact test. Settings and Design-The study was performed in the Department of Anaesthesia in Jubilee Mission Medical College and Regional Institute, Thrissur, from January 2015 to March 2016. This was a prospective study. RESULTS Age, gender and duration of surgery were comparable in both groups. The amount of sevoflurane consumed was less in group S. The postoperative pain was also less in group S at all the time points. Patients in group S demanded less rescue analgesics. 83.3% of the patients in group S had good sleep versus 26.7% in the group C. Up to 93.3% of the patients in group S had a relaxed body language versus 36.7% in group C. No adverse effects were noted. CONCLUSION Pre-emptive etoricoxib is thus a safe, simple and cost-effective therapy in reducing the intraoperative anaesthetic and postoperative analgesic requirements.

show abstract

“…Etoricoxib, a highly selective cyclooxygenase (COX)‐2 inhibitor available in many countries, has been reported to reduce postoperative pain after orthopaedic surgery (Turan, Hein, Jacobson, & Jakobsson, ). It's pharmacokinetics are linear at clinically relevant doses, and their half‐life (t1/2) of approximately 20 hr enables once‐a‐day dosing (Blaney Davidson et al, ).…”

Section: Introductionmentioning

confidence: 99%

The COX‐2 inhibitor etoricoxib reduces experimental osteoarthritis and nociception in rats: The roles of TGF‐β1 and NGF expressions in chondrocytes

Wen

Lin

Chang

et al. 2019

European Journal of Pain

View full text Add to dashboard Cite

Background Osteoarthritis (OA) is the most common joint disease, especially affecting the knee joint. Etoricoxib, a highly selective cyclooxygenase (COX)‐2 inhibitor which can reduce postoperative pain after orthopaedic surgery. The aim of this study was to investigate the effects of oral etoricoxib on the development of OA and to examine concomitant changes in the nociceptive behaviour of rats. Method OA was induced in wistar rats by anterior cruciate ligament transection (ACLT) of the right knee. The ACLT + etoricoxib groups received 6.7 or 33.3 mg/kg of oral etoricoxib three times a week for 12 consecutive weeks, starting at week 8 after ACLT. Nociceptive behaviours and changes in knee joint width during OA development were analyzed. Histopathological studies were then performed on the cartilage. Immunohistochemical analysis was performed to examine the effect of etoricoxib on the expression of transforming growth factor‐beta (TGF‐β) and nerve growth factor (NGF) in articular cartilage chondrocytes. Results OA rats receiving etoricoxib showed a significantly lower degree of cartilage degeneration than the rats receiving placebo. Nociceptive behaviour studies showed significant improvement in the ACLT + etoricoxib groups compared to that in the ACLT group. Moreover, etoricoxib attenuated NGF expression, but increased TGF‐β expression, in OA‐affected cartilage. Conclusions Oral etoricoxib in a rat OA model (a) attenuates the development of OA, (b) concomitantly reduces nociception, and (c) modulates chondrocyte metabolism, possibly by inhibiting NGF expression and increasing TGF‐β expression. Significance Oral administration of etoricoxib can attenuate the development of OA, with an associated attenuation of nociceptive behaviour in an experimental rat OA model. Moreover, etoricoxib attenuated NGF expression, but enhanced TGF‐β expression in OA‐affected chondrocytes. These findings may pave the way for further investigations of etoricoxib as a potential therapeutic target for the treatment of the inflammatory component in OA.

show abstract

Sevoflurane requirement during elective ankle day surgery: the effects of etirocoxib premedication, a prospective randomised study

Cited by 3 publications

References 21 publications

Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery—a pilot study

Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery—a pilot study

Efficacy of Pre-Emptive Etoricoxib in Patients Undergoing Hernioplasty Under General Anaesthesia- A Prospective Randomised-Controlled Trial

The COX‐2 inhibitor etoricoxib reduces experimental osteoarthritis and nociception in rats: The roles of TGF‐β1 and NGF expressions in chondrocytes

Contact Info

Product

Resources

About